SOURCE: Brower Piven, A Professional Corporation

August 19, 2011 15:45 ET

Brower Piven Encourages Investors Who Have Losses in Excess of $1,000,000 From Investment in Dendreon Corporation to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the October 3, 2011 Lead Plaintiff Deadline

STEVENSON, MD--(Marketwire - Aug 19, 2011) - Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of purchasers of the common stock of Dendreon Corporation ("Dendreon" or the "Company") (NASDAQ: DNDN) during the period between January 7, 2011 and August 3, 2011 inclusive (the "Class Period").

If you have suffered a net loss for all transactions in Dendreon Corporation common stock during the Class Period, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at, by email at, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.

No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than October 3, 2011 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You are not required to have sold your shares to seek damages or to serve as a Lead Plaintiff.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the Company's failure to disclose during the Class Period material adverse facts about the Company's business, operations, prospects and performance. According to the Complaint, after, on August 3, 2011, Dendreon revealed financial and operational results well below analysts' expectations and significantly lowered 2011 guidance due to the fact that the launch of Provenge will have a 'more gradual trajectory' than previously expected because the process of getting reimbursed discourages doctors' recommendation for the drug for treatment, the value of Dendreon stock declined significantly

If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

Contact Information

    Charles J. Piven
    Brower Piven, A Professional Corporation
    Stevenson, Maryland
    Email Contact